Randomized trial of posaconazole and benznidazole for chronic Chagas' disease.
暂无分享,去创建一个
Fernando Salvador | X. Vidal | I. Molina | F. Salvador | A. Blanco-Grau | E. Sulleiro | Albert Pahissa | A. Sánchez-Montalvá | A. Pahissa | Xavier Vidal | Israel Molina | Jordi Gómez i Prat | Begoña Treviño | Elena Sulleiro | Núria Serre | Diana Pou | Sílvia Roure | Juan Cabezos | Lluís Valerio | Albert Blanco-Grau | Adrián Sánchez-Montalvá | S. Roure | L. Valerio | J. Gómez I Prat | J. Cabezos | B. Treviño | D. Pou | N. Serre | J. Gómez i Prat | Núria Serre
[1] E. Segura,et al. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. , 1998, The American journal of tropical medicine and hygiene.
[2] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[3] S. Sauleda,et al. Development of a real-time PCR assay for Trypanosoma cruzi detection in blood samples. , 2007, Acta tropica.
[4] Simonne Almeida e Silva,et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection , 1996, The Lancet.
[5] J. Silva,et al. Antiparasitical chemotherapy in Chagas’ disease cardiomyopathy: current evidence , 2012, Tropical medicine & international health : TM & IH.
[6] J. Urbina,et al. Experimental chemotherapy with combinations of ergosterol biosynthesis inhibitors in murine models of Chagas' disease , 1993, Antimicrobial Agents and Chemotherapy.
[7] Robert H Gilman,et al. Evaluation and treatment of chagas disease in the United States: a systematic review. , 2007, JAMA.
[8] H. R. Martins,et al. Clinical and laboratory status of patients with chronic Chagas disease living in a vector-controlled area in Minas Gerais, Brazil, before and nine years after aetiological treatment. , 2009, Memorias do Instituto Oswaldo Cruz.
[9] R. López-Vélez,et al. Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis. , 2009, The Journal of antimicrobial chemotherapy.
[10] D. Loebenberg,et al. Activities of the Triazole Derivative SCH 56592 (Posaconazole) against Drug-Resistant Strains of the Protozoan ParasiteTrypanosoma (Schizotrypanum) cruzi in Immunocompetent and Immunosuppressed Murine Hosts , 2000, Antimicrobial Agents and Chemotherapy.
[11] A. Rassi,et al. Detection of parasitemia profiles by blood culture after treatment of human chronic Trypanosoma cruzi infection , 2006, Parasitology Research.
[12] A. deOliveira,et al. Clinical and radiological aspects of aperistalsis of the esophagus , 1960 .
[13] R. Isturiz,et al. Chagas Disease , 2021, Neglected Tropical Diseases.
[14] C. Bern. Antitrypanosomal therapy for chronic Chagas' disease. , 2011, The New England journal of medicine.
[15] J. Coura,et al. Chronic phase of Chagas disease: why should it be treated? A comprehensive review. , 2011, Memorias do Instituto Oswaldo Cruz.
[16] A. D. de Oliveira,et al. [Clinical and radiological aspects of aperistalsis of the esophagus]. , 1960, Revista brasileira de gastroenterologia.
[17] D. Kontoyiannis,et al. Pharmacokinetics, Safety, and Efficacy of Posaconazole in Patients with Persistent Febrile Neutropenia or Refractory Invasive Fungal Infection , 2006, Antimicrobial Agents and Chemotherapy.
[18] J. R. Cançado. Long term evaluation of etiological treatment of chagas disease with benznidazole. , 2002, Revista do Instituto de Medicina Tropical de Sao Paulo.
[19] Rodolfo Viotti,et al. Long-Term Cardiac Outcomes of Treating Chronic Chagas Disease with Benznidazole versus No Treatment , 2006, Annals of Internal Medicine.
[20] O. Lortholary,et al. Simultaneous quantification of voriconazole and posaconazole in human plasma by high-performance liquid chromatography with ultra-violet detection. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[21] A. Simoes-Barbosa,et al. Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives. , 2000, The American journal of tropical medicine and hygiene.
[22] P. Wincker,et al. Antiproliferative Effects and Mechanism of Action of SCH 56592 against Trypanosoma (Schizotrypanum)cruzi: In Vitro and In Vivo Studies , 1998, Antimicrobial Agents and Chemotherapy.
[23] J. Urbina. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. , 2010, Acta tropica.
[24] A. Taquini,et al. [Chronic Chagas cardiopathy]. , 1952, Medicina.
[25] A. Romanha,et al. Efficacy of benznidazol treatment for asymptomatic chagasic patients from state of Rio Grande do Sul evaluated during a three years follow-up. , 2009, Memorias do Instituto Oswaldo Cruz.
[26] J Sun,et al. A non-parametric test for interval-censored failure time data with application to AIDS studies. , 1996, Statistics in medicine.
[27] R. Gallerano,et al. [Interventional study in the natural evolution of Chagas disease. Evaluation of specific antiparasitic treatment. Retrospective-prospective study of antiparasitic therapy]. , 2000, Revista de la Facultad de Ciencias Médicas.
[28] A. Teixeira,et al. Persistent infections in chronic Chagas' disease patients treated with anti-Trypanosoma cruzi nitroderivatives. , 2000, Revista do Instituto de Medicina Tropical de Sao Paulo.
[29] J. Coura,et al. [Comparative controlled study on the use of benznidazole, nifurtimox and placebo, in the chronic form of Chagas' disease, in a field area with interrupted transmission. I. Preliminary evaluation]. , 1997, Revista da Sociedade Brasileira de Medicina Tropical.
[30] D. Kwon,et al. Posaconazole: a new broad-spectrum antifungal agent , 2007, Expert opinion on pharmacotherapy.
[31] G. Espinosa,et al. Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus. , 2010, The American journal of tropical medicine and hygiene.
[32] D. Fabbro,et al. Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution. , 2007, Revista da Sociedade Brasileira de Medicina Tropical.
[33] D. Fabbro,et al. [Longitudinal study and specific chemotherapy in children with chronic Chagas' disease, residing in a low endemicity area of Argentina]. , 2004, Revista da Sociedade Brasileira de Medicina Tropical.
[34] G. M. Sperandio da Silva,et al. Safety of benznidazole use in the treatment of chronic Chagas' disease. , 2012, The Journal of antimicrobial chemotherapy.
[35] G. Krishna,et al. Pharmacokinetics and Absorption of Posaconazole Oral Suspension under Various Gastric Conditions in Healthy Volunteers , 2008, Antimicrobial Agents and Chemotherapy.
[36] E. Kuschnir,et al. [Evaluation of cardiac function by radioisotopic angiography, in patients with chronic Chagas cardiopathy]. , 1985, Arquivos brasileiros de cardiologia.